Sanofi (SNY) Fair Value 2026

SNY · Drug Manufacturers - General ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.5 /10

32 fundamental signals · 11 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-27, Sanofi (SNY) trades at $44.84, versus a $72.61 median fair value across its 11 active models — 61.9% above the current price. QOC: 7.5/10. Value Trap Risk: 35/100 (LOW). 11/13 models active. Within that set, the Bayesian DCF component alone returns $98.79.

Key Facts

Ticker
SNY
Price
$44.84
Quality Score
7.5/10
Value Trap Risk
35/100
Models Active
11/13
Last Updated
Strength: Bayesian DCF suggests +120.3% upside with 71% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Is Sanofi (SNY) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Sanofi (SNY) appears undervalued as of : the median of 11 independent fair value estimates is $72.61, 61.9% above the current price of $44.84. Estimates range from $31.77 to $164.92. SNY scores 7.5/10 on fundamental quality and 35/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. SNY’s +61.9% gap is wider than that market norm, and the Drug Manufacturers - General sector median is +29.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Sanofi Stock in 2026? →

What Fair Value Does Each Model Give SNY?

11 Intrinsic Value Models vs. Current Price ($44.84)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $98.79 +120.3%
Intrinsic · High Conviction
 $72.61 +61.9%
Ensemble · Medium Conviction
 $80.11 +78.7%
Scenario · High Conviction
 $55.96 +24.8%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is SNY's Fair Value Range?

Spread across 11 independent models · $31.77 to $164.92

CirclFi's 11 active models place Sanofi (SNY) between $31.77 and $164.92 per share, a spread of 183% of the median. The median of that range — $72.61 — is the fair value CirclFi publishes for SNY, against a current price of $44.84.

Low · ML-RIVHigh · Regime Cross
$31.77median $72.61$164.92
Where the range comes from
Most bearish modelML Residual Income$31.77
Most bullish modelRegime Cross-Sectional$164.92
Model agreement9 bullish · 2 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for SNY. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on SNY, not a CirclFi price target. How each model works →

What Is Sanofi (SNY) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Sanofi's intrinsic value is estimated at a median fair value of $72.61. At a current market price of $44.84, 9 of 11 active valuation models identify upside potential, projecting a median implied return of +61.9%. Notably, Regime Cross sees the most upside at +267.8% (fair value: $164.92), while ML-RIV is the most conservative at -29.2% ($31.77). The spread between these extremes — +297.0% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, Bayesian DCF, EPV lean bullish — adding weight to the bullish side of the thesis.

What Do the Models Say About SNY?

11 of 13 models are currently active for SNY. Of these, 9 models suggest upside while 2 models suggest overvaluation. Taken together, their median fair value for SNY is $72.61 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $98.79 on its own, implying +120.3% upside from the current price. See which stocks rank higher →

How Does SNY Rank in Drug Manufacturers - General?

Among 21 Drug Manufacturers - General stocks, SNY ranks #12 by Quality of Company score. CirclFi's QOC score of 7.5/10 evaluates 32 fundamental signals. A score of 7.5 indicates above-average quality.

Sanofi's positioning within the Drug Manufacturers - General segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including orphan drug designation — shape both the opportunity set and risk profile.

Is SNY a Value Trap?

CirclFi's Value Trap algorithm assigns SNY a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Sanofi. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Sanofi scores 7.5 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +297.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SNY valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SNY's 11 active models, average confidence is 54%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Sanofi Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - General Stocks Should You Also Analyze?

10 related Drug Manufacturers - General stocks with 13-model coverage

ABBVAbbVie Inc.QOC 7.6PFEPfizer Inc.QOC 7.5BIIBBiogen Inc.QOC 7.9OGNOrganon & Co.QOC 7.3AMGNAmgen Inc.QOC 8.4GRFSGrifols, S.A.QOC 6.9SCLXScilex Holding CompanyQOC 5.2GILDGilead Sciences, Inc.QOC 9.7JNJJohnson & JohnsonQOC 9.0MRKMerck & Co., Inc.QOC 9.6

Read investment analysis: ABBV · PFE · BIIB · OGN · AMGN · GRFS · SCLX · GILD · JNJ · MRK

Which Other Stocks Have a Similar Quality Score to SNY?

7 companies across all industries closest to SNY’s Quality of Company score of 7.5/10.

LINDLindblad Expeditions Holdings, Inc.QOC 7.5HMCHonda Motor Co., Ltd.QOC 7.5MNSBMainStreet Bancshares, Inc.QOC 7.5TLKPerusahaan Perseroan (Persero) PT Telekomunikasi Indonesia TbkQOC 7.5IZEAIZEA Worldwide, Inc.QOC 7.5BRKRBruker CorporationQOC 7.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: LIND · HMC · MNSB · TLK · IZEA · BRKR · NVDA

What Else Do Investors Ask About Sanofi’s Valuation?

What is Sanofi's intrinsic value in 2026?

CirclFi puts Sanofi (SNY)'s intrinsic value at $72.61 — the median of 11 independent model estimates as of 2026-08-27, ranging from $31.77 to $164.92. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $98.79 on its own. The Quality of Company score is 7.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SNY overvalued or undervalued right now?

At $44.84, 9 of 11 active models suggest SNY may be undervalued, while 2 indicate potential overvaluation. The median of all 11 fair value estimates is $72.61, 61.9% above the current price of $44.84 — a consensus view that SNY is undervalued. The assessment depends on which methodology best fits Sanofi's business model in Drug Manufacturers - General.

What does a Quality of Company score of 7.5 mean for SNY?

Sanofi's QOC of 7.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on SNY?

CirclFi analyzes SNY with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on SNY?

Of the 11 models currently active on SNY, Regime Cross-Sectional is the most bullish at $164.92 per share, and ML Residual Income is the most bearish at $31.77. CirclFi's published fair value for SNY is the median of that range, $72.61, not either extreme. The gap between the two ends equals 183% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is SNY a value trap in 2026?

Sanofi's Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Sanofi (SNY) has a median fair value of $72.61 — 61.9% above the current price of $44.84 — as of 2026-08-27.” Source: circlfi.com/stock/SNY/ · Methodology
Primary sources for this SNY valuation
  • Financial statements: Sanofi 10-K and 10-Q filings on SEC EDGAR (CIK 0001121404) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SNY as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on SNY.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for SNY Unlock All 11 — $39/mo